Sandoz challenges Amgen's Enbrel patents in US antitrust lawsuit [Yahoo! Finance]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Yahoo! Finance
Filed at the US District Court for the Eastern District of Virginia, the suit contends that Amgen extended its market exclusivity for Enbrel by “unlawfully purchasing and using certain patent rights to entrench its position in the market”. Sandoz said this is delaying competition from biosimilar alternatives – including its own US Food and Drug Administration (FDA)-approved biosimilar Erelzi (etanercept-szzs). Although Erelzi was FDA-approved in 2016 and launched in Europe that same year, it has yet to reach US patients due to ongoing patent disputes. Sandoz is now seeking an injunction to prevent Amgen from continuing to block biosimilar entry and is also pursuing treble damages under US antitrust law. Approved in 1998, Enbrel was one of the first US Food and Drug Administration (FDA) approved biologics for autoimmune diseases like rheumatoid arthritis and psoriasis. By 2002, it had achieved blockbuster status, having surpassed the $1bn sales mark globally. Enbrel generated $3.3
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- Exploring Growth Trends in the Chemotherapy Induced Anemia Market: A Surge to USD 4.84 Billion by 2032 [Yahoo! Finance]Yahoo! Finance
- Amgen (NASDAQ:AMGN) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=AMGN&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> fromMarketBeat
- FDA Approves Amgen's UPLIZNA® (inebilizumab-cdon) for Generalized Myasthenia Gravis (gMG), Expanding Treatment Options for Patients Living with Autoimmune Neuromuscular Disease [Yahoo! Finance]Yahoo! Finance
- Amgen (NASDAQ:AMGN) was given a new $304.00 price target on by analysts at Morgan Stanley.MarketBeat
- FDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS [Yahoo! Finance]Yahoo! Finance
AMGN
Earnings
- 11/4/25 - Beat
AMGN
Sec Filings
- 11/21/25 - Form 4
- 11/20/25 - Form 144
- 11/13/25 - Form 4
- AMGN's page on the SEC website